Jade Biosciences (JBIO) Current Leases (2021 - 2025)
Jade Biosciences' (JBIO) quarterly Current Leases came in at $312000.0 in Q1 2025, down 29.89% YoY from $445000.0 in Q1 2024, and down 25.18% on a QoQ basis from $417000.0 in Q4 2024.
Jade Biosciences (JBIO) Current Leases (2021 - 2025) Analysis & Trends
Jade Biosciences (JBIO) has 5 years of Current Leases data on file, last reported at $312000.0 in Q1 2025.
- Quarterly Current Leases fell 29.89% year-over-year to $312000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $312000.0 (down 29.89% YoY) and the FY2024 annual result came in at $417000.0, down 0.71% from the prior year.
- Current Leases retreated to $312000.0 in Q1 2025, from $417000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $475000.0 in Q2 2024 to a low of $147000.0 in Q3 2021.
- A 5-year average of $358266.7 and a median of $379000.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases jumped 157.82% — and 2025, when it declined 29.89%.
- Tracing JBIO's Current Leases over 5 years: stood at $192000.0 in 2021, then surged by 100.52% to $385000.0 in 2022, then increased by 9.09% to $420000.0 in 2023, then slipped by 0.71% to $417000.0 in 2024, then dropped by 25.18% to $312000.0 in 2025.
- The last three Current Leases figures came in at $312000.0 (Q1 2025), $417000.0 (Q4 2024), and $459000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 312,000.00 |
| Dec 31, 2024 | 417,000.00 |
| Sep 30, 2024 | 459,000.00 |
| Jun 30, 2024 | 475,000.00 |
| Mar 31, 2024 | 445,000.00 |
| Dec 31, 2023 | 420,000.00 |
| Sep 30, 2023 | 451,000.00 |
| Jun 30, 2023 | 379,000.00 |
| Mar 31, 2023 | 373,000.00 |
| Dec 31, 2022 | 385,000.00 |
| Sep 30, 2022 | 379,000.00 |
| Jun 30, 2022 | 347,000.00 |
| Mar 31, 2022 | 193,000.00 |
| Dec 31, 2021 | 192,000.00 |
| Sep 30, 2021 | 147,000.00 |